The founder of RTW Investments believes biopharma’s five-year bear market is finally coming to an end.

In a client letter detailing August results, dated September 2 and obtained by Institutional Investor, the biotech hedge fund firm’s founder, Rod Wong, told clients, “We are increasingly optimistic that a biotech recovery could gain momentum. We continue to see a large number of asymmetric opportunities and are excited for a number of development-stage events and key new product launches this fall.”

Wong’s optimism is understandable. READ MORE